modelC02LG03
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | PicodralazineAndDiuretics | |
| ATC code: | C02LG03 | route: | oral |
| compartments: | 1 | |
| dosage: | 25 | mg |
| volume of distribution: | 80 | L |
| clearance: | 60 | L/h |
| other parameters in model implementation | ||
Picodralazine is a vasodilator antihypertensive agent, usually combined with diuretics for the management of high blood pressure. It is classified under the ATC code C02LG03. The combination is used to lower blood pressure in patients where monotherapy is insufficient. Picodralazine is not widely used today and is not approved in most modern formularies.
Pharmacokinetics
No published pharmacokinetic parameters specific to picodralazine and diuretics combination have been identified in the literature for any subgroup of patients. Parameters below are estimated based on typical pharmacokinetics for similar antihypertensive vasodilators administered orally in adults.
References
Wang, EB, et al., & Dickinson, GL (2017). Population Pharmacokinetics of LY2623091 in Patients With Hypertension and Chronic Kidney Disease. Journal of clinical pharmacology 57(6) 739–746. DOI:10.1002/jcph.865 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28144958
Pelligand, L, et al., & Jacobs, M (2020). Population Pharmacokinetics and Pharmacodynamics Modeling of Torasemide and Furosemide After Oral Repeated Administration in Healthy Dogs. Frontiers in veterinary science 7 151–None. DOI:10.3389/fvets.2020.00151 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32411731
Tsai, MC, et al., & Vakilynejad, M (2016). Population Pharmacokinetics and Exposure-Response of a Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With Stage 2 Hypertension. Journal of clinical pharmacology 56(8) 988–998. DOI:10.1002/jcph.684 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26632101
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)